Neurological Manifestations in Children Diagnosed With Inflammatory Bowel Disease

NCT ID: NCT07247994

Last Updated: 2025-11-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

44 participants

Study Classification

OBSERVATIONAL

Study Start Date

2026-01-01

Study Completion Date

2027-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

screen for neurologic and psychiatric disorders in children and

adolescents with IBD.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Neurologic symptoms have a great importance in early diagnosis and

treatment preventing major morbidity and later sequelae, especially if they

precede GI symptoms

The prevalence of neurologic manifestations of IBD varies between 0.2% and

36%. Their pathogenesis of neurologic manifestations in IBD consists of 6

mechanisms: 1.malabsorption and nutritional deficiency 2.metabolic agents

3.infections complicating immune suppression 4.side effects of medications or

iatrogenic as a surgical complication 5.thromboembolism 6.immunological

factors

UC patients are similar to or higher than CD patients in the probability of

neurologic symptoms. Neurologic manifestations and complications include:

headache, dizziness, hypotonia, ADHD, tics, sensory complaints, seizures,

neuropsychiatric disorders, peripherial neuropathy, meningitis, vestibular

dysfunction, idiopathic IC hypertension, cerebral vasculitis, demyelinating

disorders and migraine

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

IBD (Inflammatory Bowel Disease)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with IBD aged from from 1 to18 years old.

Exclusion Criteria

* patients with IBD and aged above 18 years old or below 1 year old
Minimum Eligible Age

1 Year

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bishoy Shehata Fahim

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Bishoy Shehata Fahim

Doctor

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nagla Hassan Abufaddan, Professor

Role: STUDY_DIRECTOR

Assiut university child hospital

Randa Kandeel Abdelaleem, Lecturer

Role: STUDY_DIRECTOR

Assiut university child hospital

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Bishoy Shehata Faheem, Resident doctor

Role: CONTACT

+201551312246

References

Explore related publications, articles, or registry entries linked to this study.

Alsakarneh S, Ahmed M, Jaber F, Abuassi M, Mourad FH, Francis FF, Barada K, Tfayli R, Al-Bawardy B, Farraye FA, Hashash JG. Inflammatory bowel disease burden in the Middle East and North Africa Region: a comprehensive analysis of incidence, prevalence, and mortality from 1990-2019. Ann Gastroenterol. 2024 Sep-Oct;37(5):527-535. doi: 10.20524/aog.2024.0909. Epub 2024 Aug 19.

Reference Type RESULT
PMID: 39238799 (View on PubMed)

Kliegman, Nathan J. Blum, Robert C. Tasker, Karen M. Wilson, Joseph W. St Geme, Abigail M. Schuh, Cara L. Mack, Matthew A. Deadorf, Nelson textbook of pediatrics edition 22, Elseveir, vol 2, 2024, pp 2309- 2325.

Reference Type RESULT

Ben-Or O, Zelnik N, Shaoul R, Pacht A, Lerner A. The neurologic profile of children and adolescents with inflammatory bowel disease. J Child Neurol. 2015 Apr;30(5):551-7. doi: 10.1177/0883073814521296. Epub 2014 Apr 2.

Reference Type RESULT
PMID: 24700662 (View on PubMed)

Zhao M, Gonczi L, Lakatos PL, Burisch J. The Burden of Inflammatory Bowel Disease in Europe in 2020. J Crohns Colitis. 2021 Sep 25;15(9):1573-1587. doi: 10.1093/ecco-jcc/jjab029.

Reference Type RESULT
PMID: 33582812 (View on PubMed)

Mosli M, Alawadhi S, Hasan F, Abou Rached A, Sanai F, Danese S. Incidence, Prevalence, and Clinical Epidemiology of Inflammatory Bowel Disease in the Arab World: A Systematic Review and Meta-Analysis. Inflamm Intest Dis. 2021 Sep 7;6(3):123-131. doi: 10.1159/000518003. eCollection 2021 Sep.

Reference Type RESULT
PMID: 34722642 (View on PubMed)

ulia Gorospe, Joseph Windsor, Lindsay Hracs, Stephanie coward, Michael Buie, Joshua Quan, Lea Caplan, Trends in infammatory bowel disease incidence and prevalence across epidemiologic stages: a global systematic review with meta-analysis, the crohns and colitis foundation and AGA institute, 2024.

Reference Type RESULT

Gordon H, Burisch J, Ellul P, Karmiris K, Katsanos K, Allocca M, Bamias G, Barreiro-de Acosta M, Braithwaite T, Greuter T, Harwood C, Juillerat P, Lobaton T, Muller-Ladner U, Noor N, Pellino G, Savarino E, Schramm C, Soriano A, Michael Stein J, Uzzan M, van Rheenen PF, Vavricka SR, Vecchi M, Zuily S, Kucharzik T. ECCO Guidelines on Extraintestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis. 2024 Jan 27;18(1):1-37. doi: 10.1093/ecco-jcc/jjad108. No abstract available.

Reference Type RESULT
PMID: 37351850 (View on PubMed)

Rogler G, Singh A, Kavanaugh A, Rubin DT. Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management. Gastroenterology. 2021 Oct;161(4):1118-1132. doi: 10.1053/j.gastro.2021.07.042. Epub 2021 Aug 3.

Reference Type RESULT
PMID: 34358489 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EIMs in Children with IBD

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.